US 7,579,445 B2
	Reagents and methods for inducing an immune response to prostate specific antigen
Beatrice Leveugle, Edmonton (Canada); Ragupathy Madiyalakan, Edmonton (Canada); Antoine A. Noujaim, Edmonton (Canada); and Birgit C. Schultes, Arlington, Mass. (US)
Assigned to AltaRex Medical Corp., Edmonton, Alberta (Canada)
Filed on Oct. 14, 2004, as Appl. No. 10/966,789.
Application 10/966789 is a continuation of application No. 09/332866, filed on Jun. 15, 1999, granted, now 6,881,405.
Claims priority of provisional application 60/089281, filed on Jun. 15, 1998.
Prior Publication US 2005/0202018 A1, Sep. 15, 2005
Int. Cl. C07K 16/00 (2006.01)

U.S. Cl. 530—387.1  [530/387.7; 530/388.1; 424/130.1; 435/7.1]

9 Claims

1. A composition for the treatment of prostate cancer, comprising a composition comprising an isolated antibody or antigen-binding fragment thereof produced by a hybridoma having ATCC Accession No. 12526 that specifically binds to circulating PSA (Prostate Specific Antigen) and induces a therapeutic immune response, and wherein the binding of the antibody or antigen-binding fragment thereof to PSA is not inhibited by the polypeptide of SEQ ID NO: 2, 3 or 4.